Janet Jill Hopkins, Chief Medical Officer of Aura Biosciences, Inc. (NASDAQ:AURA), filed a Form 4 on September 1, 2026, reporting the receipt of restricted stock units and a stock option award under the company's 2021 Stock Option and Incentive Plan.
Key Highlights
- RSU Grant: Hopkins received 58,850 restricted stock units at a price of $0, each representing the right to receive one share of common stock upon vesting.
- Stock Option Grant: Hopkins was awarded a stock option to purchase 116,150 shares of common stock at an exercise price of $7.43 per share, expiring September 1, 2036.
- RSU Vesting Schedule: The RSUs vest in four substantially equal annual installments, with the first tranche vesting on September 15, 2027, subject to continued service.
- Option Vesting Schedule: The stock option vests as to 1/48th of the total award monthly, with the first tranche vesting on October 1, 2026, subject to continued service.
- Post-Transaction Ownership: Following the reported transactions, Hopkins directly owns 380,190 shares of common stock and holds 116,150 derivative securities beneficially.
Aura Biosciences CMO Equity Awards: RSUs and Options Reported
According to the Form 4 filed with the SEC, Janet Jill Hopkins, serving as Chief Medical Officer of Aura Biosciences, Inc., received two equity awards on September 1, 2026. The first is a grant of 58,850 restricted stock units under the issuer's 2021 Stock Option and Incentive Plan. The filing states that each RSU represents the right to receive one share of the issuer's common stock upon vesting and settlement, and that the acquisition price was $0.
The RSUs are scheduled to vest in four substantially equal annual installments, with vesting conditioned on the reporting person's continued service to the issuer on each vesting date. The first tranche is set to vest on September 15, 2027, according to the filing's explanation of responses.
The second award is a stock option granting Hopkins the right to buy 116,150 shares of common stock at an exercise price of $7.43 per share, with an expiration date of September 1, 2036. The filing discloses that this option vests as to 1/48th of the total award on a monthly basis, subject to continued service, with the first monthly tranche vesting on October 1, 2026. Both awards were granted at a derivative security price of $0. Following these transactions, the filing reports Hopkins' direct beneficial ownership of common stock at 380,190 shares.
What Was Disclosed
The filing discloses two equity awards granted to Aura Biosciences' Chief Medical Officer on September 1, 2026: 58,850 RSUs vesting annually over four years and a stock option for 116,150 shares at $7.43, vesting monthly over 48 months.




Please wait processing your request...